Meridian Bioscience, Inc.

Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol

Role: lead

Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis

Role: collaborator

Clinical Decision Rules in the Emergency Department to Improve the Management of Acute Respiratory Infection and Acute Infectious Diarrhea

Role: collaborator

BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis

Role: lead

Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection

Role: lead

BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency

Role: lead

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

Role: lead

13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)

Role: lead

Assessing Portal Hypertension With Methacetin Breath Test

Role: lead

Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

Role: lead

BreathID Multi-center HCV Liver Breath Test Study

Role: lead

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14

Role: lead

Equivalence of New Breath AnalyzerCompared to Currently BreathID System in Assessment of Liver Function

Role: lead

Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection

Role: lead

Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics

Role: lead

Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI

Role: lead

BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH

Role: lead

Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis

Role: lead

MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy

Role: lead

Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation

Role: lead